Tebuconazole
Based on 3 publication(s) in Google Scholar
Tebuconazole is an orally active agricultural azole fungicide which can also inhibit CYP51 with IC50s of 0.9 and 1.3 μM for Candida albicans CYP51 (CaCYP51) and truncated Homo sapiens CYP51 (Δ60HsCYP51), respectively. Tebuconazole induces lipid accumulation and oxidative stress in HepG2 Cells. Tebuconazole decreases MAC-T cells viability and proliferation, induces ER-stress-mediated apoptosis and increases oxidative stress levels in MAC-T cells.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.63%
- CAS No.: 107534-96-3
- Formule: C16H22ClN3O
- Masse moléculaire:307.82
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Oxygen Sensing Compound Library
HY-L045
-
Antifungal Compound Library
HY-L048
-
Ferroptosis Compound Library
HY-L051
-
Endoplasmic Reticulum Stress Compound Library
HY-L054
-
Orally Active Compound Library
HY-L061
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Mitochondria-Targeted Compound Library
HY-L089
-
Human Metabolite Library
HY-L123
-
Metabolic Enzyme Compound Library
HY-L146
-
Cell Death Library
HY-L162
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Pesticide Compound Library
HY-L183
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Environmental Pollutant Compound Library
HY-L247
Publications Citing Use of MedChemExpress (MCE) Tebuconazole
More
Activité biologique
|
CYP51 |
Tebuconazole (TEB) (20–80 μM, 24 h) shows lipid accumulation in HepG2 cells[2].
Tebuconazole (20–80 μM, 12 h) increases the nuclear translocation of peroxisome proliferator-activated receptors and the expression of lipid uptake and oxidation-related markers in HepG2
cells[2].
Tebuconazole (20–80 μM, 24 h) increases oxidative stress levels, induces the loss of mitochondrial membrane potential and lower levels of microsomal triglyceride transfer protein in the HepG2 cells[2].
Tebuconazole (0-750 μM, 24 hours) decreases MAC-T cells viability and proliferation and induced mitochondria-mediated apoptotic MAC-T cell death by activating ER stress[3].
Tebuconazole (0-100 μM, 24 hours) induces dose-dependent cell death in H9c2 cardiomyoblasts and in adult rat ventricular myocytes (ARVM)[4].
Tebuconazole (30-60 μM, 24 hours) induces DNA damage and ROS generation and lipid peroxidation in H9c2 cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HepG2 cells
-
Concentration:20,40,80 μM
-
Incubation Time:1–12 hours
-
Result:Increased the nuclear translocation of peroxisome proliferator-activated receptors and the expression of cluster of differentiation 36, fatty acid transport protein (FATP) 2, FATP5, and carnitine palmitoyltransferase 1.
-
Cell Line:Bovine mammary gland epithelial cells (MAC-T cells)
-
Concentration:100,150,200,250,500,750 μM
-
Incubation Time:24 hours
-
Result:Decreased cells viability and proliferation and activates apoptotic cell death via the upregulation of pro-apoptotic proteins, such as cleaved caspases 3 and 8 and BAX.
Induced loss of mitochondrial membrane potential in MAC-T cells.
Induced mitochondria-mediated apoptotic MAC-T cell death by activating ER stress.
Induced endoplasmic reticulum (ER) stress via the upregulation of Bip/GRP78; PDI; ATF4; CHOP; and ERO1-Lα.
Tebuconazole (25-100 mg/kg, p.o., daily for 10 days) causes the proliferation of fetal Leydig cells and increases fetal serum testosterone and progesterone levels in gestational rat[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Wistar rats[5]
-
Dosage:10, 25, and 50 mg/kg
-
Administration:p. o. once daily for 28 days
-
Result:Induced CYP1A1/2, CYP2B1/2, CYP2E1, and CYP3A proteins in liver.
Decreased glutathione content and increased glutathione S-transferase, superoxide dismutase, catalase, and glutathione peroxidase activities in liver .
Increased superoxide dismutase activities in kidney and testis.
Decreased glutathione S-transferase activity in testis .
Decreased serum testosterone concentration and cauda epididymal sperm count .
-
Animal Model:Male and female Sprague-Dawley rats[6]
-
Dosage:25, 50, and 100 mg/kg
-
Administration:Oral gavage (p.o.), for 10 days
-
Result:Increased fetal serum testosterone and progesterone levels.
Increased the number of fetal Leydig cells per testis without inducing cell aggregation.
Up-regulated the expression levels of Star, Cyp11a1, Hsd17b3, and Fshr.
Increased phosphorylation of AKT1, ERK1/2, and mTOR, the level of BCL2, as well as the decrease of Beclin1, LC3B, and BAX.
Chemical Information
-
CAS No. 107534-96-3
-
Appearance Solid
-
Masse moléculaire 307.82
-
Formule C16H22ClN3O
-
Color White to off-white
-
SMILES
CC(C)(C)C(O)(CCC1=CC=C(Cl)C=C1)CN2C=NC=N2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Autophagy
MoSec13 combined with MoGcn5b modulates MoAtg8 acetylation and regulates autophagy in Magnaporthe oryzae. [Abstract]2025 May 9:1-18. PMID: 40320672 -
Virulence
2025 Dec;16(1):2472877. PMID: 40033930 -
Mol Genet Metab
Expansion of genotype/phenotype correlation in an individual with compound heterozygous variants in CYP51A1 and congenital cataract. [Abstract]2025 Sep 2;146(1-2):109230. PMID: 40912167
Solvant et solubilité
DMSO : ≥ 50 mg/mL (162.43 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.12 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.12 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 20 mg/mL (64.97 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (282 KB)
-
SDS (701 KB)
- English - EN (701 KB)
- Français - FR (701 KB)
- Deutsch - DE (701 KB)
- Norwegian - NO (701 KB)
- Español - ES (701 KB)
- Swedish - SV (701 KB)
- Italian - IT (701 KB)
- Korean - KR (701 KB)
- Portuguese - PT (701 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Warrilow AG, et al. Azole affinity of sterol 14α-demethylase (CYP51) enzymes from Candida albicans and Homo sapiens. Antimicrob Agents Chemother. 2013 Mar;57(3):1352-60. [Content Brief]
[2]. Kwon HC, et.al. Tebuconazole Fungicide Induces Lipid Accumulation and Oxidative Stress in HepG2 Cells. Foods. 2021 Sep 22;10(10):2242. [Content Brief]
[3]. Lee WY, et.al. Tebuconazole Induces ER-Stress-Mediated Cell Death in Bovine Mammary Epithelial Cell Lines. Toxics. 2023 Apr 21;11(4):397. [Content Brief]
[4]. Ben Othmène Y,et.al. Tebuconazole induces ROS-dependent cardiac cell toxicity by activating DNA damage and mitochondrial apoptotic pathway. Ecotoxicol Environ Saf. 2020 Nov;204:111040. [Content Brief]
[5]. Yang JD, et.al. Effects of tebuconazole on cytochrome P450 enzymes, oxidative stress, and endocrine disruption in male rats. Environ Toxicol. 2018 Jun 19. [Content Brief]
[6]. Ma F, et.al. Gestational exposure to tebuconazole affects the development of rat fetal Leydig cells. Chemosphere. 2021 Jan;262:127792. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2487 mL | 16.2433 mL | 32.4865 mL | 81.2163 mL |
| 5 mM | 0.6497 mL | 3.2487 mL | 6.4973 mL | 16.2433 mL | |
| 10 mM | 0.3249 mL | 1.6243 mL | 3.2487 mL | 8.1216 mL | |
| 15 mM | 0.2166 mL | 1.0829 mL | 2.1658 mL | 5.4144 mL | |
| 20 mM | 0.1624 mL | 0.8122 mL | 1.6243 mL | 4.0608 mL | |
| 25 mM | 0.1299 mL | 0.6497 mL | 1.2995 mL | 3.2487 mL | |
| 30 mM | 0.1083 mL | 0.5414 mL | 1.0829 mL | 2.7072 mL | |
| 40 mM | 0.0812 mL | 0.4061 mL | 0.8122 mL | 2.0304 mL | |
| 50 mM | 0.0650 mL | 0.3249 mL | 0.6497 mL | 1.6243 mL | |
| 60 mM | 0.0541 mL | 0.2707 mL | 0.5414 mL | 1.3536 mL | |
| 80 mM | 0.0406 mL | 0.2030 mL | 0.4061 mL | 1.0152 mL | |
| 100 mM | 0.0325 mL | 0.1624 mL | 0.3249 mL | 0.8122 mL |
Tebuconazole Related Classifications
HY-B0852 Related Classifications
Powered by Bioz